RSS

respiratory syncytial virus (RSV)

Biotechnology company, Bavarian Nordic, has revealed positive data from the extension study of its Phase II study investigating its universal respiratory syncytial virus (RSV) vaccine, MVA-BN RSV, in older adults. more

News

Antiviral drug discovery and development company, ReViral, has successfully completed its Series B financing round, raising $55 million in funding. more

News

Biotechnology company, VirionHealth, has raised series A funding of up to £13 million from an international investment group dedicated to the life sciences, Abingworth. more

News

Regeneron Pharmaceuticals has announced plans to discontinue further clinical development of its antibody, suptavumab, for respiratory syncytial virus, as it has not met the primary endpoint of preventing infections in infants in the Phase III study more

News